[{"orgOrder":0,"company":"Dexcel Pharma","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dexcel Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Dexcel Pharma \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dexcel Pharma \/ SK Biopharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Dexcel Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : Dexcel holds exclusive commercialization rights to Xcopri (cenobamate), is an antiseizure medication for epilepsy in Israel.

                          Product Name : Xcopri

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          May 03, 2023

                          Lead Product(s) : Cenobamate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : SK Biopharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank